Radiation techniques in aggressive pituitary tumours and carcinomas

Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018 Jan;178(1):G1–24.

McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265–76.

Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol. 2017 May;176(5):645–55.

Vance ML. Pituitary radiotherapy. Endocrinol Metab Clin N Am. 2005 Jun;34(2):479–87 xi.

Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord. 2009 Jun;10(2):135–44.

Minniti G, Flickinger J. The risk/benefit ratio of radiotherapy in pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;16:101269.

Chanson P, Dormoy A, Dekkers O. Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol. 2019 May;1.

Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, et al. Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg. 2013;119(2):446–56.

Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol. 1998;48(3):331–7.

Minniti G, Scaringi C, Poggi M, Jaffrain Rea ML, Trillò G, Esposito V, et al. Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol. 2015;172(4):433–41.

Ogawa Y, Jokura H, Niizuma K, Tominaga T. Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant? J Neuro-Oncol. 2018 May;137(3):543–9.

Pomeraniec IJ, Dallapiazza RF, Xu Z, Jane JA, Sheehan JP. Early versus late gamma knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. J Neurosurg. 2016;125(1):202–12.

Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S, et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):239–47.

Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, et al. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. J Clin Endocrinol Metab. 2017;102(9):3368–74.

Verma J, McCutcheon IE, Waguespack SG, Mahajan A. Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas. Pituitary. 2014 Dec;17(6):539–45.

Castinetti F, Régis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol. 2010 Apr;6(4):214–23.

Ding D, Mehta GU, Patibandla MR, Lee C-C, Liscak R, Kano H, et al. Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study. Neurosurgery. 2019 Mar 1;84(3):717–25.

Mehta GU, Ding D, Patibandla MR, Kano H, Sisterson N, Su Y-H, et al. Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study. J Clin Endocrinol Metab. 2017;102(11):4284–91.

Hung Y-C, Lee C-C, Yang H-C, Mohammed N, Kearns KN, Nabeel AM, et al. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study. J Neurosurg. 2019 Aug;2:1–10.

Shimon I, Jallad RS, Fleseriu M, Yedinak CG, Greenman Y, Bronstein MD. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. Eur J Endocrinol. 2015;172(6):707–13.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res. 2008;14(3):931–8.

Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009;75(1):212–9.

Ilie MD, Lasolle H, Raverot G. Emerging and novel treatments for pituitary tumors. J Clin Med. 2019;25:8(8).

Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci. 2017;41:75–7.

Dutta P, Reddy KS, Rai A, Madugundu AK, Solanki HS, Bhansali A, et al. Surgery, Octreotide, Temozolomide, Bevacizumab, radiotherapy, and Pegvisomant treatment of an AIP mutation–positive child. J Clin Endocrinol Metab. 2019;104(8):3539–44.

Cordeiro D, Xu Z, Mehta G, Ding D, Vance ML, Kano H, et al. Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: a multicenter, international study. J Neurosurg. 2018;09.

Burman P, van Beek AP, Biller BMK, Camacho-Hübner C, Mattsson AF. Radiotherapy, especially at Young age, increases the risk for De novo brain tumors in patients treated for pituitary/Sellar lesions. J Clin Endocrinol Metab. 2017;102(3):1051–8.